GlassScriptPhysician profile
Jonathan Weinberger
NPI 1851735419
$5,267.07
in general payments reported to CMS, 2019-2025
47 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $517 · 2021: $786 · 2022: $484 · 2023: $719 · 2024: $1,024 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.89 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $559.46 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $357.43 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $272.81 | 2024-2025 | |
| Madrigal Pharmaceuticals | $217.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $183.03 | 2019-2024 | Dificid |
| Pfizer INC. | $160.79 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $154.09 | 2023-2024 | Terlivaz |
| Gilead Sciences, INC. | $151.70 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $126.63 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $124.50 | 2022 | |
| Celgene Corporation | $124.38 | 2021-2023 | Zeposia |
| Biogen, INC. | $115.59 | 2025 | Vumerity, Tysabri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $102.41 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weinberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.